Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of the Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa (RP)
Conditions
Interventions
human retinal progenitor cells
Locations
3
United States
Gavin Herbert Eye Inst, Univ Cal Irvine
Irvine, California, United States
Retina-Vitreous Associates Medical Group
Los Angeles, California, United States
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States
Start Date
December 1, 2020
Primary Completion Date
March 22, 2022
Completion Date
March 22, 2022
Last Updated
July 16, 2024
NCT05926583
NCT07174726
NCT07292987
NCT06789445
NCT04639635
NCT06628947
Lead Sponsor
jCyte, Inc
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions